Alnylam Pharmaceuticals, Inc.
(NASDAQ : ALNY)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-2.13%199.081.3%$749.78m
GILDGilead Sciences, Inc.
-2.66%62.510.9%$372.82m
CELGCelgene Corporation
-1.80%93.991.3%$323.19m
ALXNAlexion Pharmaceuticals, Inc.
-6.61%115.332.0%$295.67m
ILMNIllumina, Inc.
-3.17%279.443.5%$272.03m
BIIBBiogen Inc.
-2.68%225.851.3%$258.17m
VRTXVertex Pharmaceuticals Incorporated
-2.20%180.181.9%$251.48m
EXASExact Sciences Corporation
-0.77%116.9624.1%$238.08m
REGNRegeneron Pharmaceuticals, Inc.
-2.77%286.852.6%$193.57m
AAgilent Technologies, Inc.
-3.01%69.581.6%$188.95m
SRPTSarepta Therapeutics, Inc.
-1.54%93.6114.7%$184.96m
BMRNBioMarin Pharmaceutical Inc.
-2.12%75.764.3%$97.12m
INCYIncyte Corporation
-4.27%81.912.5%$90.56m
GHDXGenomic Health, Inc.
-0.35%73.261.8%$81.69m
NBIXNeurocrine Biosciences, Inc.
0.36%97.595.0%$71.75m

Company Profile

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.